Research

Hormonal

In real-world clinical practice, semaglutide produces attenuated weight loss (average 4.44%) compared to clinical trials, with diabetes mellitus diagnosis significantly reducing efficacy while linaclotide use and prediabetes are associated with enhanced weight loss.

If you are taking semaglutide in a standard clinical setting, expect an average weight loss of around 4-5% over a year, which is less than the 10-15% often cited from clinical trials. This difference is largely due to the lack of intensive lifestyle counseling provided in routine care. If you have diabetes, your weight loss may be further reduced, whereas having prediabetes or taking linaclotide might actually help you lose more weight.

GoodQualifiesHIGH confidence
On average, individuals lost 4.44% (male individuals, 3.66%; female individuals, 5.08%) of their initial weight. History of diabetes mellitus diagnosis was associated with less weight loss, whereas prediabetes and linaclotide use were associated with more pronounced weight loss.
William C. Powell et al. · Obesity · 2023

Why this rating

Large real-world observational study (n=3555) with robust machine learning feature analysis, though not a randomized controlled trial.

Source

Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world data

William C. Powell et al. · Obesity · 2023

DOI 10.1002/oby.23859

cohort · n=3555Cited 27×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →